Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Buy rating on Humacyte (NASDAQ:HUMA) and maintains a $15 price target.
March 25, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Buy rating on Humacyte and maintains a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a Benchmark analyst could positively influence investor sentiment towards Humacyte, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100